文献速递肥胖与代谢综合征糖尿病

胰岛素抵抗逆转是代谢手术后NASH长期缓解的核心驱动因素

Insulin Resistance Is Central to Long-Term Reversal of Histologic Nonalcoholic Steatohepatitis After Metabolic Surgery.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该前瞻性5年随访研究在37例接受胆胰转流术(BPD)的患者中评估组织学非酒精性脂肪性肝炎(NASH)逆转的决定因素。随访时56.5%的患者NASH逆转,NAFLD活动评分从3.7±0.93降至2±1.11(P<.001),纤维化逆转占16%(P=.022)、改善占32%(95%CI 0.05-0.54)。除术后胰岛素敏感性指标外,BMI及临床参数变化均不能解释手术对NASH的效果,神经网络分析显示研究终点Matsuda指数区分应答者与非应答者的AUC达0.98%。结论认为NASH缓解由干预后全身胰岛素抵抗逆转所驱动。

要点

  • BPD术后5年56.5%患者NASH组织学逆转,NAS从3.7±0.93降至2±1.11(P<.001)。
  • 术后HOMA-IR从3.31±1.72降至1.73±1.08(P<.001),Matsuda指数从2.66±1.79升至4.73±3.05(P<.001)。
  • 终点Matsuda指数区分NASH应答者与非应答者的ROC AUC为0.98%。

核心结论

  • NASH缓解由代谢手术后全身胰岛素抵抗的逆转所驱动,而非BMI或临床参数变化。

研究设计与样本

  • 前瞻性5年随访研究,在Policlinico Universitario Agostino Gemelli开展,共37例患者接受BPD并在术中及术后5年行肝活检。
  • 主要结局为5年随访时组织学NASH逆转,并比较NASH未逆转与已消失患者的临床变量。

主要发现

  • 随访时56.5%的患者NASH逆转,NAS从3.7±0.93降至2±1.11(P<.001)。
  • 纤维化逆转占16%(P=.022),改善占32%(95%CI 0.05-0.54)。
  • 除术后胰岛素敏感性指标外,BMI或临床参数变化均不能解释手术对NASH的效果。
  • HOMA-IR从3.31±1.72降至1.73±1.08(P<.001),Matsuda指数从2.66±1.79升至4.73±3.05(P<.001)。
  • 血脂谱正常化:总胆固醇从4.75±1.18降至3.32±0.77 mmol/L(P<.001),LDL-C从2.92±0.91降至1.60±0.51 mmol/L(P=.0001),HDL-C从0.97±0.33升至1.10±0.35 mmol/L(P=.023),甘油三酯从2.52±1.6降至1.47±0.67 mmol/L(P=.003)。

临床怎么用

  • 在代谢手术后NASH管理中,应重视全身胰岛素抵抗的评估与逆转,而非仅关注体重或BMI变化。
  • Matsuda指数或可作为识别NASH组织学应答者的胰岛素敏感性指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Nonalcoholic steatohepatitis (NASH) is considered the hepatic counterpart of metabolic syndrome. OBJECTIVE: This work aimed to investigate the determinants of NASH reversal in patients undergoing biliopancreatic diversion (BPD) in a 5-year follow-up study. METHODS: This prospective study was conducted at Policlinico Universitario Agostino Gemelli. A total of 37 patients underwent fine-needle liver biopsy during BPD. Ultrasonography-guided percutaneous liver biopsy was obtained 5 years after the operation. The primary outcome of our study was histologic NASH reversal at 5-year follow-up. To better characterize the clinical variables involved in the resolution of NASH, we also compared patients without histologic NASH resolution at 5 years with those in whom NASH had disappeared. RESULTS: At follow-up, NASH had reversed in 56.5% of the patients. The NAFLD activity score (NAS) improved from 3.7 ± 0.93 to 2 ± 1.11 (P < .001). Fibrosis reversed in 16% patients (P = .022), and 32% improved (95% CI, 0.05-0.54). No significant differences in body mass index or clinical parameters changes explained the effect of surgery on NASH, apart from the measure of insulin sensitivity post surgery. The Homeostasis Model Assessment of Insulin Resistance decreased from 3.31 ± 1.72 at baseline to 1.73 ± 1.08 (P < .001) after BPD, and the Matsuda index improved from 2.66 ± 1.79 to 4.73 ± 3.05 (P < .001). The lipid profile normalized (total cholesterol from 4.75 ± 1.18 to 3.32 ± 0.77 mmol/L, P < .001; low-density lipoprotein cholesterol from 2.92 ± 0.91 to 1.60 ± 0.51 mmol/L, P = .0001; high-density lipoprotein cholesterol from 0.97 ± 0.33 to 1.10 ± 0.35 mmol/L, P = .023; triglycerides from 2.52 ± 1.6 to 1.47 ± 0.67 mmol/L, P = .003). Neural network analysis showed that the end-study Matsuda index discriminated between responders and nonresponders with high accuracy (receiver operating characteristic area under the curve = 0.98%). CONCLUSION: Remission of NASH is driven by reversal of whole-body insulin resistance post intervention.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Russo MF, Lembo E, Mari A, et al. Insulin Resistance Is Central to Long-Term Reversal of Histologic Nonalcoholic Steatohepatitis After Metabolic Surgery. J Clin Endocrinol Metab. 2021. PMID: 33248441. doi:10.1210/clinem/dgaa892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。